1 |
1- deoxygalactonojirimycin |
- |
- |
- |
- |
019 [1] 19 💬 |
2 |
1-deoxygalactonojirimycin |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
3 |
1-deoxygalactonojirimycin hydrochloride |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
4 |
12s-it |
- |
- |
- |
- |
019 [1] 19 💬 |
5 |
15 o water |
Water |
[1] D00001 D00001 💬 |
- |
- |
019 [1] 19 💬 |
6 |
2(s)-(acetylamino)-4-methylpentanoic acid |
- |
- |
- |
- |
019 [1] 19 💬 |
7 |
2-aminoethanethiol |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [2] 19, 299 💬 |
8 |
2-hydroxypropyl-beta-cyclodextrin |
Betadex |
[1] D02401 D02401 💬 |
- |
- |
019 [1] 19 💬 |
9 |
4d-310 |
- |
- |
- |
- |
019 [1] 19 💬 |
10 |
500 0500 0 |
- |
- |
- |
- |
019 [1] 19 💬 |
11 |
89 zirconium recombinant human alpha-n-acetylglucosaminidase (rhnaglu) (radiolabeled) |
- |
- |
- |
- |
019 [1] 19 💬 |
12 |
89zr-sbc-103 |
- |
- |
- |
- |
019 [1] 19 💬 |
13 |
[045251016] |
- |
- |
- |
- |
019 [1] 19 💬 |
14 |
[14c] at1001 |
- |
- |
- |
- |
019 [1] 19 💬 |
15 |
[a16ab04] |
- |
- |
- |
- |
019 [1] 19 💬 |
16 |
[at1001] |
- |
- |
- |
- |
019 [1] 19 💬 |
17 |
[hgt-1410] |
- |
- |
- |
- |
019 [1] 19 💬 |
18 |
[otl-200] |
- |
- |
- |
- |
019 [1] 19 💬 |
19 |
[rhlaman] |
Velmanase alfa |
[1] D11024 D11024 💬 |
MAN2B1 [1] MAN2B1 💬 |
Lysosome [2] Lysosome, Other glycan degradation |
019 [1] 19 💬 |
20 |
[shp611] |
- |
- |
- |
- |
019 [1] 19 💬 |
21 |
A (migalastat) |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
22 |
A16ab04 |
- |
- |
- |
- |
019 [1] 19 💬 |
23 |
A16ax06 |
- |
- |
- |
- |
019 [1] 19 💬 |
24 |
Aav2/8.tbg.harsb |
- |
- |
- |
- |
019 [1] 19 💬 |
25 |
Aav2cuhcln2 (3x10^12 particle units) |
- |
- |
- |
- |
019 [1] 19 💬 |
26 |
Aav9-cag-coh-sgsh |
- |
- |
- |
- |
019 [1] 19 💬 |
27 |
Aav9-glb1 |
- |
- |
- |
- |
019 [1] 19 💬 |
28 |
Aavrh.10-hmpsiiia |
- |
- |
- |
- |
019 [1] 19 💬 |
29 |
Aavrh.10cuarsa |
- |
- |
- |
- |
019 [1] 19 💬 |
30 |
Aavrh.10cucln2 |
- |
- |
- |
- |
019 [1] 19 💬 |
31 |
Aavrh.10cuhcln2 vector 2.85x10^11 genome copies |
- |
- |
- |
- |
019 [1] 19 💬 |
32 |
Aavrh.10cuhcln2 vector 9.0x10^11 genome copies |
- |
- |
- |
- |
019 [1] 19 💬 |
33 |
Abatacept |
Abatacept |
[1] D03203 D03203 💬 |
CD80 [2] CD80, CD86 💬 |
Allograft rejection [12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
011 [26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |
34 |
Abo-101 |
- |
- |
- |
- |
019 [1] 19 💬 |
35 |
Abo-102 |
- |
- |
- |
- |
019 [1] 19 💬 |
36 |
Accupro |
- |
- |
- |
- |
019 [1] 19 💬 |
37 |
Accuretic |
- |
- |
- |
- |
019 [1] 19 💬 |
38 |
Acetylcysteine |
Acetylcysteine |
[1] D00221 D00221 💬 |
- |
- |
006 [16] 6 , 13, 19, 20, 34, 49, 51, 58, 85, 94, 111, 164, 193, 233, 298, 299 💬 |
39 |
Act-434964 |
- |
- |
- |
- |
019 [1] 19 💬 |
40 |
Adalimumab |
Adalimumab |
[1] D02597 D02597 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
019 [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬 |
41 |
Adalimumab injection [humira] |
Adalimumab |
[1] D02597 D02597 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
019 [1] 19 💬 |
42 |
Adeno-associated viral (aav) serotype 8 (aav2/8) vector with liver-specific thyroxine-binding globulin (tbg) promoter, driving the expression of the human arsb gene |
Levothyroxine |
[2] D01010 D01010, D08125 D08125 💬 |
THRA [2] THRA, THRB 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
019 [1] 19 💬 |
43 |
Adeno-associated viral vector serotype 9 containing the human n-acetyl-alpha-glucosaminidase gene |
- |
- |
- |
- |
019 [1] 19 💬 |
44 |
Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase a cdna |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
45 |
Adeno-associated virus serotype 2/6 encoding human iduronate 2-sulfatase (hids) gene donor vector, sb-a6p-hnt donor vector |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
46 |
Adeno-associated virus serotype 2/6 encoding human iduronidase (hidua) gene donor vector, sb-a6p-hrl donor vector |
- |
- |
- |
- |
019 [1] 19 💬 |
47 |
Adeno-associated virus serotype 2/6 encoding left side-zinc finger nuclease (zfn1), sb-a6p-zleft vector |
- |
- |
- |
- |
019 [1] 19 💬 |
48 |
Adeno-associated virus serotype 2/6 encoding right side-zinc finger nuclease (zfn2), sb-a6p-zright vector |
- |
- |
- |
- |
019 [1] 19 💬 |
49 |
Administration |
- |
- |
- |
- |
019 [1] 19 💬 |
50 |
Adrabetadex |
Adrabetadex |
- |
- |
- |
019 [1] 19 💬 |
51 |
Afegostat |
Afegostat |
[1] D09576 D09576 💬 |
- |
- |
019 [1] 19 💬 |
52 |
Afegostat tartrate |
Afegostat |
[1] D09576 D09576 💬 |
- |
- |
019 [1] 19 💬 |
53 |
Agalsidase |
- |
- |
- |
- |
019 [1] 19 💬 |
54 |
Agalsidase alfa |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
55 |
Agalsidase alpha |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
56 |
Agalsidase beta |
Agalsidase beta |
[1] D03228 D03228 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
57 |
Agalsidase beta (gz419828) |
Agalsidase beta |
[1] D03228 D03228 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
58 |
Agalsidase beta (recombinant form) |
Agalsidase beta |
[1] D03228 D03228 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
59 |
Agalsidasi beta |
- |
- |
- |
- |
019 [1] 19 💬 |
60 |
Agt-181 |
- |
- |
- |
- |
019 [1] 19 💬 |
61 |
Agt-181 (hirmab-idua) |
- |
- |
- |
- |
019 [1] 19 💬 |
62 |
Agt-182 |
- |
- |
- |
- |
019 [1] 19 💬 |
63 |
Aldurazyme |
- |
- |
- |
- |
019 [1] 19 💬 |
64 |
Aldurazyme (laronidase) |
Laronidase |
[1] D04670 D04670 💬 |
IDUA [1] IDUA 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [2] 19, 256 💬 |
65 |
Aldurazyme (recombinant human alpha-l-iduronidase) |
- |
- |
- |
- |
019 [1] 19 💬 |
66 |
Aldurazyme*infus 1fl 5ml 500u |
- |
- |
- |
- |
019 [1] 19 💬 |
67 |
Alemtuzumab |
Alemtuzumab |
[1] D02802 D02802 💬 |
- |
- |
013 [16] 13, 15, 19, 20, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 💬 |
68 |
Alendronate |
Alendronic acid |
[2] D00939 D00939, D07119 D07119 💬 |
FDPS [1] FDPS 💬 |
Human T-cell leukemia virus 1 infection [4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
019 [7] 19, 41, 46, 50, 271, 274, 299 💬 |
69 |
Alendronate sodium |
Alendronic acid |
[2] D00939 D00939, D07119 D07119 💬 |
FDPS [1] FDPS 💬 |
Human T-cell leukemia virus 1 infection [4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
019 [2] 19, 299 💬 |
70 |
Alfa-manosidadas humana recombinante |
- |
- |
- |
- |
019 [1] 19 💬 |
71 |
Alpha-galactosidase a |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
72 |
Ambroxol |
Ambroxol |
[1] D07442 D07442 💬 |
- |
- |
006 [2] 6 , 19 💬 |
73 |
Anakinra |
Anakinra |
[1] D02934 D02934 💬 |
IL1R1 [2] IL1R1, IL1R2 💬 |
Amoebiasis [15] Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
002 [17] 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 84, 86, 97, 106, 107, 299 💬 |
74 |
Angiotensin |
Angiotensin II |
[2] D00150 D00150, D02014 D02014 💬 |
AGTR1 [2] AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications [16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
017 [7] 17, 19, 46, 66, 86, 222, 224 💬 |
75 |
Arimoclomol |
Arimoclomol |
[1] D11374 D11374 💬 |
- |
- |
002 [3] 2 , 15, 19 💬 |
76 |
Arimoclomol (hard gelatine capsule) |
Arimoclomol |
[3] D00115 D00115, D06892 D06892, D11374 D11374 💬 |
- |
- |
019 [1] 19 💬 |
77 |
Arimoclomol (hpmc capsule) |
Arimoclomol |
[1] D11374 D11374 💬 |
- |
- |
019 [1] 19 💬 |
78 |
Arimoclomol citrate |
Arimoclomol |
[1] D11374 D11374 💬 |
- |
- |
015 [2] 15, 19 💬 |
79 |
Arylsulfatase a |
- |
- |
- |
- |
019 [1] 19 💬 |
80 |
At1001 |
- |
- |
- |
- |
019 [1] 19 💬 |
81 |
At1001 150 mg |
- |
- |
- |
- |
019 [1] 19 💬 |
82 |
At2101 |
- |
- |
- |
- |
019 [1] 19 💬 |
83 |
Ataluren |
Ataluren |
[1] D09323 D09323 💬 |
- |
- |
019 [6] 19, 113, 140, 246, 299, 329 💬 |
84 |
Autologous cd34+ cells transduced with a lentiviral vector containing the human sgsh gene |
- |
- |
- |
- |
019 [1] 19 💬 |
85 |
Autologous cd34+ cells transduced with a lentiviral vector encoding the arsa cdna |
- |
- |
- |
- |
019 [1] 19 💬 |
86 |
Autologous plasmablasts |
- |
- |
- |
- |
019 [1] 19 💬 |
87 |
Avr-rd-01 |
- |
- |
- |
- |
019 [1] 19 💬 |
88 |
Avr-rd-02 |
- |
- |
- |
- |
019 [1] 19 💬 |
89 |
Ax |
- |
- |
- |
- |
019 [1] 19 💬 |
90 |
Ax 250 |
- |
- |
- |
- |
019 [1] 19 💬 |
91 |
Azathioprine |
Azathioprine |
[2] D00238 D00238, D03033 D03033 💬 |
- |
- |
006 [20] 6 , 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 94, 95, 96, 97, 162 💬 |
92 |
Azathioprine (aza) |
Azathioprine |
[2] D00238 D00238, D03033 D03033 💬 |
- |
- |
013 [3] 13, 19, 97 💬 |
93 |
B (migalastat) |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
94 |
Barium |
Barium |
- |
- |
- |
019 [2] 19, 98 💬 |
95 |
Behavioral: neurocognitive testing |
- |
- |
- |
- |
019 [1] 19 💬 |
96 |
Behavioral: picc line placement |
- |
- |
- |
- |
019 [1] 19 💬 |
97 |
Beta-cyclodextrin |
Betadex |
[1] D02401 D02401 💬 |
- |
- |
019 [1] 19 💬 |
98 |
Beta-mercaptoethylamine |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
99 |
Beta-mercaptoethylamine hydrochloride & 2-aminoethanethiol hydrochloride |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
100 |
Bhp001 |
- |
- |
- |
- |
019 [1] 19 💬 |
101 |
Biological assays |
- |
- |
- |
- |
019 [1] 19 💬 |
102 |
Biopsy |
- |
- |
- |
- |
019 [2] 19, 51 💬 |
103 |
Blood sampling |
- |
- |
- |
- |
013 [5] 13, 17, 19, 51, 96 💬 |
104 |
Bm110 |
- |
- |
- |
- |
019 [1] 19 💬 |
105 |
Bmn 110 |
- |
- |
- |
- |
019 [1] 19 💬 |
106 |
Bmn 110 - every other week |
- |
- |
- |
- |
019 [1] 19 💬 |
107 |
Bmn 110 - weekly |
- |
- |
- |
- |
019 [1] 19 💬 |
108 |
Bmn 110 every other week |
- |
- |
- |
- |
019 [1] 19 💬 |
109 |
Bmn 110 weekly |
- |
- |
- |
- |
019 [1] 19 💬 |
110 |
Bmn 190 |
- |
- |
- |
- |
019 [1] 19 💬 |
111 |
Bmn 250 |
- |
- |
- |
- |
019 [1] 19 💬 |
112 |
Bmn190 recombinant human tripeptidyl peptidase-1 (rhtpp1) |
- |
- |
- |
- |
019 [1] 19 💬 |
113 |
Brineura |
- |
- |
- |
- |
019 [1] 19 💬 |
114 |
Busilvex |
- |
- |
- |
- |
019 [4] 19, 36, 60, 65 💬 |
115 |
Busilvex - 6 mg/ml - concentrato per soluzione per infusione - uso endovenoso - flaconcino - 10 ml 8 flaconcini |
- |
- |
- |
- |
019 [2] 19, 65 💬 |
116 |
Busulfan |
Busulfan |
[1] D00248 D00248 💬 |
- |
- |
019 [13] 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 💬 |
117 |
Busulfan, cyclophosphamide, antithymocyte globulin |
Busulfan |
[3] D00248 D00248, D00287 D00287, D07760 D07760 💬 |
- |
- |
019 [2] 19, 20 💬 |
118 |
Busulfan, cyclophosphamide, atg |
Busulfan |
[3] D00248 D00248, D00287 D00287, D07760 D07760 💬 |
- |
- |
019 [1] 19 💬 |
119 |
Busulfano |
Busulfan |
[1] D00248 D00248 💬 |
- |
- |
019 [1] 19 💬 |
120 |
C (migalastat) |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
121 |
Calcium |
Calcium |
- |
- |
- |
006 [27] 6 , 13, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 186, 214, 215, 222, 224, 235, 265, 274, 298, 299 💬 |
122 |
Calcium carbonate |
Calcium |
[2] D00932 D00932, D10802 D10802 💬 |
- |
- |
013 [8] 13, 19, 46, 53, 75, 96, 235, 299 💬 |
123 |
Cald hr-d (high-risk, regimen c) |
- |
- |
- |
- |
019 [5] 19, 20, 125, 234, 326 💬 |
124 |
Cald hr-d (high-risk, regimen d) |
- |
- |
- |
- |
019 [5] 19, 20, 125, 234, 326 💬 |
125 |
Cald sr-a (standard-risk, regimen a) |
- |
- |
- |
- |
019 [5] 19, 20, 125, 234, 326 💬 |
126 |
Cald sr-b (standard-risk, regimen b) |
- |
- |
- |
- |
019 [5] 19, 20, 125, 234, 326 💬 |
127 |
Campath |
- |
- |
- |
- |
019 [12] 19, 20, 49, 51, 60, 62, 65, 164, 234, 283, 285, 326 💬 |
128 |
Campath-1h |
- |
- |
- |
- |
019 [6] 19, 20, 60, 234, 285, 326 💬 |
129 |
Capsaicin |
Capsaicin |
[1] D00250 D00250 💬 |
TRPV1 [1] TRPV1 💬 |
Inflammatory mediator regulation of TRP channels [2] Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
002 [5] 2 , 6 , 19, 86, 226 💬 |
130 |
Carbonate |
Carbonate ion |
- |
- |
- |
002 [12] 2 , 13, 17, 18, 19, 46, 53, 75, 96, 127, 235, 299 💬 |
131 |
Cellule cd34+ autologhe trasdotte con idua lv codificante per il cdna dell'alfa-l-iduronidasi |
- |
- |
- |
- |
019 [1] 19 💬 |
132 |
Cerdelga |
- |
- |
- |
- |
019 [1] 19 💬 |
133 |
Ceredase |
- |
- |
- |
- |
019 [1] 19 💬 |
134 |
Ceredase™ |
- |
- |
- |
- |
019 [1] 19 💬 |
135 |
Cerezyme |
- |
- |
- |
- |
019 [1] 19 💬 |
136 |
Cerezyme (imiglucerase for injection) |
Imiglucerase |
[2] D02810 D02810, D03020 D03020 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
137 |
Cerezyme® |
- |
- |
- |
- |
019 [1] 19 💬 |
138 |
Cerezyme® / imiglucerase |
Imiglucerase |
[2] D02810 D02810, D03020 D03020 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
139 |
Cerliponase alfa |
Cerliponase alfa |
[1] D10813 D10813 💬 |
TPP1 [1] TPP1 💬 |
Lysosome [1] Lysosome |
019 [1] 19 💬 |
140 |
Chemically modified recombinant human sulfamidase |
- |
- |
- |
- |
019 [1] 19 💬 |
141 |
Cholecalciferol |
Cholecalciferol |
[1] D00188 D00188 💬 |
VDR [1] VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption [4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
013 [9] 13, 19, 34, 46, 49, 96, 97, 298, 299 💬 |
142 |
Cholesterol |
Cholesterol |
[1] D00040 D00040 💬 |
- |
- |
019 [6] 19, 90, 160, 259, 261, 310 💬 |
143 |
Clofarabine |
Clofarabine |
[1] D03546 D03546 💬 |
POLA1 [3] POLA1, POLA2, RRM1 💬 |
DNA replication [6] DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 [9] 19, 20, 40, 46, 49, 60, 96, 234, 326 💬 |
144 |
Coversyl |
- |
- |
- |
- |
019 [2] 19, 167 💬 |
145 |
Coversyl plus |
- |
- |
- |
- |
019 [1] 19 💬 |
146 |
Cryopreserved autologous cd34+ cells transduced with a lentiviral vector containing human sgsh gene |
- |
- |
- |
- |
019 [1] 19 💬 |
147 |
Csa |
- |
- |
- |
- |
019 [8] 19, 49, 50, 53, 60, 63, 222, 228 💬 |
148 |
Cyclophosphamide |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
011 [44] 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 💬 |
149 |
Cyclosporine |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 [35] 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 63, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 💬 |
150 |
Cyclosporine a |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
019 [10] 19, 20, 36, 49, 50, 53, 58, 60, 234, 283 💬 |
151 |
Cyclosporine a (csa) |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
019 [2] 19, 60 💬 |
152 |
Cystadane anhydrous |
- |
- |
- |
- |
019 [1] 19 💬 |
153 |
Cystadrops |
- |
- |
- |
- |
019 [1] 19 💬 |
154 |
Cystadrops 0.55% eye drops, solution |
- |
- |
- |
- |
019 [1] 19 💬 |
155 |
Cystagon |
- |
- |
- |
- |
008 [3] 8 , 19, 299 💬 |
156 |
Cystagon 150mg |
- |
- |
- |
- |
019 [1] 19 💬 |
157 |
Cystagon 50mg |
- |
- |
- |
- |
019 [1] 19 💬 |
158 |
Cystagon® |
- |
- |
- |
- |
019 [1] 19 💬 |
159 |
Cystagon® (cysteamine bitartrate) |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
160 |
Cysteamine |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
008 [4] 8 , 19, 21, 299 💬 |
161 |
Cysteamine (mercaptamine) viscous solution |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
162 |
Cysteamine bitartrate |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
008 [4] 8 , 19, 21, 299 💬 |
163 |
Cysteamine bitartrate (inn: mercaptamine bitartrate |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
164 |
Cysteamine bitartrate (inn: mercaptamine bitartrate ) |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
165 |
Cysteamine bitartrate (inn: mercaptamine bitartrate) |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
166 |
Cysteamine bitartrate delayed-release capsules |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
167 |
Cysteamine bitartrate delayed-release capsules (rp103) |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
168 |
Cysteamine hydrochloride |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
169 |
Cysteine |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
006 [11] 6 , 13, 19, 34, 84, 85, 88, 90, 254, 296, 310 💬 |
170 |
D (migalastat) |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
171 |
Device: administration kit |
- |
- |
- |
- |
019 [1] 19 💬 |
172 |
Device: cyclosporine a |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
019 [2] 19, 20 💬 |
173 |
Device: intraventricular access device |
- |
- |
- |
- |
019 [1] 19 💬 |
174 |
Device: mechanical stimulation with von frey filaments |
- |
- |
- |
- |
019 [1] 19 💬 |
175 |
Device: mri with contrast agent injection |
- |
- |
- |
- |
019 [1] 19 💬 |
176 |
Device: mri without contrast agent injection |
- |
- |
- |
- |
019 [1] 19 💬 |
177 |
Device: osome |
- |
- |
- |
- |
019 [1] 19 💬 |
178 |
Device: temperature sensitivity measurement with advanced thermal stimulation |
- |
- |
- |
- |
019 [1] 19 💬 |
179 |
Diagnostic test: audiology assessmentwith abr |
- |
- |
- |
- |
019 [1] 19 💬 |
180 |
Diagnostic test: bone density scan (dexa |
- |
- |
- |
- |
019 [1] 19 💬 |
181 |
Diagnostic test: echocardiogram |
- |
- |
- |
- |
019 [1] 19 💬 |
182 |
Diagnostic test: echocardiography at m24 |
- |
- |
- |
- |
019 [1] 19 💬 |
183 |
Diagnostic test: echocardiography at t0 |
- |
- |
- |
- |
019 [1] 19 💬 |
184 |
Diagnostic test: electrocardiogram (ekg) |
- |
- |
- |
- |
019 [1] 19 💬 |
185 |
Diagnostic test: exercise test |
- |
- |
- |
- |
019 [1] 19 💬 |
186 |
Diagnostic test: laboratory tests |
- |
- |
- |
- |
019 [1] 19 💬 |
187 |
Dnl310 |
- |
- |
- |
- |
019 [1] 19 💬 |
188 |
Dnl310 drug substance |
- |
- |
- |
- |
019 [1] 19 💬 |
189 |
Dried blood spot (dbs) sampling |
- |
- |
- |
- |
019 [1] 19 💬 |
190 |
Drx005b |
- |
- |
- |
- |
019 [1] 19 💬 |
191 |
Duoc-01 |
- |
- |
- |
- |
019 [2] 19, 20 💬 |
192 |
E (migalastat) |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
193 |
Elaprase |
- |
- |
- |
- |
019 [1] 19 💬 |
194 |
Elaprase 2mg/ml |
- |
- |
- |
- |
019 [1] 19 💬 |
195 |
Elaprase for intravenous (iv) infusion |
- |
- |
- |
- |
019 [1] 19 💬 |
196 |
Elaprase_0.5mg/kg |
- |
- |
- |
- |
019 [1] 19 💬 |
197 |
Elelyso |
- |
- |
- |
- |
019 [1] 19 💬 |
198 |
Elelyso 60 units/kg |
- |
- |
- |
- |
019 [1] 19 💬 |
199 |
Eliglustat |
Eliglustat |
[1] D09893 D09893 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
200 |
Eliglustat gz385660 |
Eliglustat |
[1] D09893 D09893 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
201 |
Eliglustat tartrate |
Eliglustat |
[1] D09893 D09893 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
202 |
Elosulfase alfa |
Elosulfase alfa |
[1] D10333 D10333 💬 |
GALNS [1] GALNS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
203 |
Elosulfase alfa 1 mg/ml intravenous solution [vimizim] |
Elosulfase alfa |
[1] D10333 D10333 💬 |
GALNS [1] GALNS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
204 |
Elx-02 |
ELX-02 |
- |
- |
- |
019 [2] 19, 299 💬 |
205 |
Enalapril |
Enalapril |
[2] D00621 D00621, D07892 D07892 💬 |
ACE [1] ACE 💬 |
Chagas disease [6] Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
019 [7] 19, 46, 66, 113, 210, 222, 223 💬 |
206 |
Enalapril and other angiotensin converting enzyme inhibitors |
Angiotensin II |
[4] D00150 D00150, D00621 D00621, D02014 D02014, D07892 D07892 💬 |
ACE [3] ACE, AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications [18] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
019 [1] 19 💬 |
207 |
Enriched hematopoetic stem cell infusion |
- |
- |
- |
- |
013 [3] 13, 19, 284 💬 |
208 |
Enzyme replacement |
- |
- |
- |
- |
019 [1] 19 💬 |
209 |
Enzyme replacement therapy |
- |
- |
- |
- |
019 [1] 19 💬 |
210 |
Enzyme replacement therapy (agalsidase alpha (replagal®)) |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
211 |
Enzyme replacement therapy (ert) |
- |
- |
- |
- |
019 [1] 19 💬 |
212 |
Ert |
- |
- |
- |
- |
019 [1] 19 💬 |
213 |
Fabrazyme |
- |
- |
- |
- |
019 [1] 19 💬 |
214 |
Fabrazyme (agalsidase beta) |
Agalsidase beta |
[1] D03228 D03228 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
215 |
Fabrazyme - 35 mg polvere per concentrato per soluzione per infusione endovenosa 1 flaconcino |
- |
- |
- |
- |
019 [1] 19 💬 |
216 |
Fabrazyme 35 mg |
- |
- |
- |
- |
019 [1] 19 💬 |
217 |
Fabrazyme 5 mg |
- |
- |
- |
- |
019 [1] 19 💬 |
218 |
Flt190 |
- |
- |
- |
- |
019 [1] 19 💬 |
219 |
Fludarabina |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 [2] 19, 65 💬 |
220 |
Fludarabina accord - 25 mg/ml concentrato per soluzione iniettabile o per infusione 5 flaconcini in vetro da 2 ml |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 [1] 19 💬 |
221 |
Fludarabina fosfato |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 [1] 19 💬 |
222 |
Fluorescein |
Fluorescein |
[2] D01261 D01261, D02024 D02024 💬 |
- |
- |
019 [2] 19, 97 💬 |
223 |
Ga-gcb |
Velaglucerase alfa |
[1] D09029 D09029 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
224 |
Ga-gcb (velaglucerase alfa) |
Velaglucerase alfa |
[1] D09029 D09029 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
225 |
Gabapentin |
Gabapentin |
[1] D00332 D00332 💬 |
CACNA2D1 [5] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 |
Adrenergic signaling in cardiomyocytes [9] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
006 [5] 6 , 13, 19, 70, 298 💬 |
226 |
Galafold |
- |
- |
- |
- |
019 [1] 19 💬 |
227 |
Galsulfase |
Galsulfase |
[1] D06565 D06565 💬 |
ARSB [1] ARSB 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
228 |
Gc1111_0.5mg/kg |
- |
- |
- |
- |
019 [1] 19 💬 |
229 |
Gc1111_1.0mg/kg |
- |
- |
- |
- |
019 [1] 19 💬 |
230 |
Gc1119 |
- |
- |
- |
- |
019 [1] 19 💬 |
231 |
Gelatine |
Gelatin |
[2] D00115 D00115, D06892 D06892 💬 |
- |
- |
019 [1] 19 💬 |
232 |
Gene activated human glucocerebrosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
233 |
Gene activated human glucocerebrosidase, velaglucerase alfa |
Velaglucerase alfa |
[1] D09029 D09029 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
234 |
Gene-activated human glucocerebrosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
235 |
Gene-activated human glucocerebrosidase 200u/vial |
- |
- |
- |
- |
019 [1] 19 💬 |
236 |
Gene-activated human glucocerebrosidase 400u/vial |
- |
- |
- |
- |
019 [1] 19 💬 |
237 |
Genetic: gla gene |
- |
- |
- |
- |
019 [1] 19 💬 |
238 |
Genetic: lys-gm101 |
- |
- |
- |
- |
019 [1] 19 💬 |
239 |
Genistein |
Genistein |
[1] D11680 D11680 💬 |
- |
- |
019 [2] 19, 299 💬 |
240 |
Genistein aglycone |
Genistein |
[1] D11680 D11680 💬 |
- |
- |
019 [1] 19 💬 |
241 |
Genz-112638 |
- |
- |
- |
- |
019 [1] 19 💬 |
242 |
Genz-682452 |
Venglustat |
[1] D11633 D11633 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
006 [3] 6 , 19, 67 💬 |
243 |
Genz-682452-aa |
Venglustat |
[1] D11633 D11633 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
244 |
Genz-682452-au |
Venglustat |
[1] D11633 D11633 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
006 [3] 6 , 19, 67 💬 |
245 |
Gla |
- |
- |
- |
- |
013 [2] 13, 19 💬 |
246 |
Glucocerebrosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
247 |
Glucocerebrosidase umano gene-attivato |
- |
- |
- |
- |
019 [1] 19 💬 |
248 |
Gnr-055 |
- |
- |
- |
- |
019 [1] 19 💬 |
249 |
Gr181413 |
- |
- |
- |
- |
019 [1] 19 💬 |
250 |
Gr181413a |
- |
- |
- |
- |
019 [1] 19 💬 |
251 |
Gr181413a/at1001 capsule |
- |
- |
- |
- |
019 [1] 19 💬 |
252 |
Gr181413a/at1001 solution |
- |
- |
- |
- |
019 [1] 19 💬 |
253 |
Growth hormone |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
002 [12] 2 , 13, 19, 46, 78, 96, 187, 191, 193, 195, 265, 299 💬 |
254 |
Gsk2788723 |
- |
- |
- |
- |
019 [1] 19 💬 |
255 |
Gz/sar402671 |
- |
- |
- |
- |
006 [2] 6 , 19 💬 |
256 |
Gz385660 |
- |
- |
- |
- |
019 [1] 19 💬 |
257 |
Gz402665 |
- |
- |
- |
- |
019 [1] 19 💬 |
258 |
Gz402671 |
- |
- |
- |
- |
019 [2] 19, 67 💬 |
259 |
Gz402671 / sar402671 |
- |
- |
- |
- |
019 [1] 19 💬 |
260 |
Hematopoetic stem cell transplantation |
- |
- |
- |
- |
019 [5] 19, 65, 120, 160, 326 💬 |
261 |
Hematopoietic stem cell infusion |
- |
- |
- |
- |
019 [2] 19, 20 💬 |
262 |
Hematopoietic stem cell transplantation |
- |
- |
- |
- |
011 [12] 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285 💬 |
263 |
Heparán n sulfatasa humana recombinante |
- |
- |
- |
- |
019 [1] 19 💬 |
264 |
Heparán n sulfatasa humana recombinante (rhhns) |
- |
- |
- |
- |
019 [1] 19 💬 |
265 |
Hgt-1110 |
- |
- |
- |
- |
019 [1] 19 💬 |
266 |
Hgt-1111 |
- |
- |
- |
- |
019 [1] 19 💬 |
267 |
Hgt-1410 |
- |
- |
- |
- |
019 [1] 19 💬 |
268 |
Hgt-2310 |
- |
- |
- |
- |
019 [1] 19 💬 |
269 |
Hids donor |
- |
- |
- |
- |
019 [1] 19 💬 |
270 |
Hucns-sc |
- |
- |
- |
- |
019 [1] 19 💬 |
271 |
Human glucocerebrosidase (prgcd) |
Taliglucerase alfa |
[1] D09675 D09675 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
272 |
Human placental derived stem cell |
- |
- |
- |
- |
019 [4] 19, 20, 60, 284 💬 |
273 |
Hunterase |
Idursulfase beta |
[1] D11025 D11025 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
274 |
Hydroxypropyl-beta-cyclodextrin |
Betadex |
[1] D02401 D02401 💬 |
- |
- |
019 [1] 19 💬 |
275 |
Hydroxypropyl-ß-cyclodextrin |
- |
- |
- |
- |
019 [1] 19 💬 |
276 |
Hydroxyurea |
Hydroxyurea |
[1] D00341 D00341 💬 |
RRM2 [1] RRM2 💬 |
Drug metabolism - other enzymes [6] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
003 [8] 3 , 13, 19, 20, 65, 85, 86, 284 💬 |
277 |
I2s |
- |
- |
- |
- |
019 [1] 19 💬 |
278 |
I2s-it |
- |
- |
- |
- |
019 [1] 19 💬 |
279 |
Ib1001 |
- |
- |
- |
- |
019 [1] 19 💬 |
280 |
Iduronate 2-sulfatase |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
281 |
Iduronate-2-sulfatase enzyme replacement therapy |
- |
- |
- |
- |
019 [1] 19 💬 |
282 |
Iduronate-2-sulfatase fused to a fc polypeptide that binds to the human transferrin receptor |
- |
- |
- |
- |
019 [1] 19 💬 |
283 |
Idursulfasa |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
284 |
Idursulfase |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
285 |
Idursulfase (i2s) |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
286 |
Idursulfase (i2s)-it |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
287 |
Idursulfase beta |
Idursulfase |
[2] D04499 D04499, D11025 D11025 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
288 |
Idursulfase it (1 mg) |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
289 |
Idursulfase it (10 mg) |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
290 |
Idursulfase it (30 mg) |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
291 |
Idursulfase(12s)-it |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
292 |
Idursulfase(i2s)-it |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
293 |
Idursulfase-it |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
294 |
Igf2 |
- |
- |
- |
- |
019 [1] 19 💬 |
295 |
Imd |
- |
- |
- |
- |
019 [5] 19, 20, 125, 234, 326 💬 |
296 |
Imd preparative regimen |
- |
- |
- |
- |
019 [5] 19, 20, 125, 234, 326 💬 |
297 |
Imiglucerasa |
Imiglucerase |
[2] D02810 D02810, D03020 D03020 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
298 |
Imiglucerase |
Imiglucerase |
[2] D02810 D02810, D03020 D03020 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
299 |
Imiglucerase gz437843 |
Imiglucerase |
[2] D02810 D02810, D03020 D03020 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
300 |
Imiglucerasi |
- |
- |
- |
- |
019 [1] 19 💬 |
301 |
Imiglucérase (drug) pharmacokinetics |
- |
- |
- |
- |
019 [1] 19 💬 |
302 |
Inactive reminder capsules |
- |
- |
- |
- |
019 [1] 19 💬 |
303 |
Inactive reminder product |
- |
- |
- |
- |
019 [1] 19 💬 |
304 |
Inn not available |
- |
- |
- |
- |
019 [2] 19, 46 💬 |
305 |
Innozide |
- |
- |
- |
- |
019 [1] 19 💬 |
306 |
Intrathecal recombinant human alpha iduronidase |
- |
- |
- |
- |
019 [1] 19 💬 |
307 |
Iohexol |
Iohexol |
[1] D01817 D01817 💬 |
- |
- |
019 [2] 19, 67 💬 |
308 |
Irt laronidase |
Laronidase |
[1] D04670 D04670 💬 |
IDUA [1] IDUA 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
309 |
Isofagamine tartrate |
- |
- |
- |
- |
019 [1] 19 💬 |
310 |
Isu302 |
- |
- |
- |
- |
019 [1] 19 💬 |
311 |
Iv migalastat hcl |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
312 |
Iva 336 |
- |
- |
- |
- |
019 [1] 19 💬 |
313 |
Jr-141 |
- |
- |
- |
- |
019 [1] 19 💬 |
314 |
Jr-141 or idursulfase |
Idursulfase |
[1] D04499 D04499 💬 |
IDS [1] IDS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
315 |
Jr-171 |
- |
- |
- |
- |
019 [1] 19 💬 |
316 |
Kanuma |
- |
- |
- |
- |
019 [1] 19 💬 |
317 |
Lamazym |
Velmanase alfa |
[1] D11024 D11024 💬 |
MAN2B1 [1] MAN2B1 💬 |
Lysosome [2] Lysosome, Other glycan degradation |
019 [1] 19 💬 |
318 |
Laronidase |
Laronidase |
[1] D04670 D04670 💬 |
IDUA [1] IDUA 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [2] 19, 256 💬 |
319 |
Laronidase ert |
Laronidase |
[1] D04670 D04670 💬 |
IDUA [1] IDUA 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
320 |
Ledipasvir |
Ledipasvir |
[1] D10442 D10442 💬 |
- |
- |
019 [1] 19 💬 |
321 |
Ledipasvir/sofosbuvir |
Ledipasvir |
[2] D10366 D10366, D10442 D10442 💬 |
- |
- |
019 [1] 19 💬 |
322 |
Lenograstim |
Lenograstim |
[1] D03247 D03247 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 [7] 2 , 13, 16, 18, 19, 57, 65 💬 |
323 |
Lentivirus alpha-gal a transduced stem cells |
- |
- |
- |
- |
019 [1] 19 💬 |
324 |
Lentivirus-mediated delivery of arsa to the cns. |
- |
- |
- |
- |
019 [1] 19 💬 |
325 |
Leucine |
Leucine |
[1] D00030 D00030 💬 |
- |
- |
005 [10] 5 , 6 , 7 , 19, 96, 97, 127, 283, 284, 299 💬 |
326 |
Leucovorin |
Leucovorin |
[3] D01211 D01211, D07986 D07986, D07987 D07987 💬 |
- |
- |
019 [2] 19, 46 💬 |
327 |
Lipasa ácida lisosómica, esterasa, colesterol (gen humano lipa), lipasa ácida lisosómica (gen humano lipa) |
- |
- |
- |
- |
019 [1] 19 💬 |
328 |
Lisinopril |
Lisinopril |
[2] D00362 D00362, D08131 D08131 💬 |
ACE [1] ACE 💬 |
Chagas disease [6] Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
019 [7] 19, 46, 49, 66, 67, 113, 222 💬 |
329 |
Lithium carbonate |
Carbonate ion |
[1] D00801 D00801 💬 |
- |
- |
002 [6] 2 , 13, 17, 18, 19, 127 💬 |
330 |
Lopace |
- |
- |
- |
- |
019 [1] 19 💬 |
331 |
Losartan |
Losartan |
[2] D00357 D00357, D08146 D08146 💬 |
AGTR1 [1] AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications [16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
017 [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬 |
332 |
Losartan and other angiotensin receptor blockers |
Angiotensin II |
[4] D00150 D00150, D00357 D00357, D02014 D02014, D08146 D08146 💬 |
AGTR1 [2] AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications [16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
019 [1] 19 💬 |
333 |
Lucerastat |
Lucerastat |
[1] D11439 D11439 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
334 |
Lys |
- |
- |
- |
- |
019 [1] 19 💬 |
335 |
Lys-saf302 |
- |
- |
- |
- |
019 [1] 19 💬 |
336 |
Lysodase |
- |
- |
- |
- |
019 [1] 19 💬 |
337 |
Lysosomal acid lipase, esterase cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa) |
Cholesterol |
[1] D00040 D00040 💬 |
- |
- |
019 [1] 19 💬 |
338 |
Lysosomal acid lipase, esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa) |
Cholesterol |
[1] D00040 D00040 💬 |
- |
- |
019 [1] 19 💬 |
339 |
Mabthera |
- |
- |
- |
- |
011 [22] 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 💬 |
340 |
Mabthera - 2 fiale 100 mg 10 ml |
- |
- |
- |
- |
019 [2] 19, 65 💬 |
341 |
Medication to suppress the immune system |
- |
- |
- |
- |
019 [1] 19 💬 |
342 |
Melphalan |
Melphalan |
[1] D00369 D00369 💬 |
- |
- |
011 [15] 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299 💬 |
343 |
Mepsevii |
- |
- |
- |
- |
019 [1] 19 💬 |
344 |
Mercaptamina |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
345 |
Mercaptamine |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
346 |
Mercaptamine bitartrate |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
347 |
Mercaptamine hydrochloride |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
348 |
Mercaptamine, mercamine, 2-aminoethanethiol |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
349 |
Metazym |
- |
- |
- |
- |
019 [1] 19 💬 |
350 |
Methotrexate |
Methotrexate |
[2] D00142 D00142, D02115 D02115 💬 |
DHFR [2] DHFR, DHFR2 💬 |
Antifolate resistance [5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
011 [35] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬 |
351 |
Methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [44] 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
352 |
Migalastat |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
353 |
Migalastat hcl |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
354 |
Migalastat hcl 150 mg |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
355 |
Migalastat hydrochloride |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
356 |
Migalastat hydrocloride |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
357 |
Miglustat |
Miglustat |
[1] D05032 D05032 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [3] 19, 256, 299 💬 |
358 |
Miglustat (zavesca) |
Miglustat |
[1] D05032 D05032 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
359 |
Monitor |
Methamidophos |
- |
- |
- |
002 [18] 2 , 11, 13, 19, 46, 49, 58, 65, 70, 85, 86, 98, 113, 118, 129, 298, 299, 300 💬 |
360 |
Moss-agal (recombinant human alpha-galactosidase a produced in moss) |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
361 |
Mozobil |
- |
- |
- |
- |
019 [3] 19, 65, 285 💬 |
362 |
Mozobil - 20 mg/ml - soluzione iniettabile - uso sottocutaneo - f |
- |
- |
- |
- |
019 [1] 19 💬 |
363 |
Mycophenolate |
Mycophenolic acid |
[1] D05096 D05096 💬 |
IMPDH1 [2] IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes [3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 [34] 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬 |
364 |
Mycophenolate mofetil |
Mycophenolate mofetil |
[4] D00752 D00752, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 [2] IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes [3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 [32] 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬 |
365 |
Mycophenylate mofetil |
- |
- |
- |
- |
019 [2] 19, 20 💬 |
366 |
Myelostim - 34 1 flaconcino liofilizzato 33.6 miu + siringa preriempita solvente 1 ml |
- |
- |
- |
- |
019 [2] 19, 65 💬 |
367 |
N acetyl cysteine |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
006 [2] 6 , 19 💬 |
368 |
N acetyl l leucine |
Leucine |
[1] D00030 D00030 💬 |
- |
- |
019 [1] 19 💬 |
369 |
N-acetyl cysteine |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
013 [7] 13, 19, 34, 85, 88, 296, 310 💬 |
370 |
N-acetyl-l-leucine |
Leucine |
[1] D00030 D00030 💬 |
- |
- |
019 [1] 19 💬 |
371 |
N-acetylcysteine |
Acetylcysteine |
[1] D00221 D00221 💬 |
- |
- |
006 [10] 6 , 13, 19, 20, 49, 58, 85, 111, 164, 299 💬 |
372 |
N-acetylgalactosamine 4-sulfatase |
- |
- |
- |
- |
019 [1] 19 💬 |
373 |
N-acetylgalactosamine-6-sulfatase |
Elosulfase alfa |
[1] D10333 D10333 💬 |
GALNS [1] GALNS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
374 |
Naglazyme |
- |
- |
- |
- |
019 [1] 19 💬 |
375 |
Naglazyme (galsulfase) |
Galsulfase |
[1] D06565 D06565 💬 |
ARSB [1] ARSB 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
376 |
Naglazyme® |
- |
- |
- |
- |
019 [1] 19 💬 |
377 |
Non applicable |
- |
- |
- |
- |
010 [2] 10, 19 💬 |
378 |
Odiparcil |
Odiparcil |
- |
- |
- |
019 [1] 19 💬 |
379 |
Ogt 918 |
- |
- |
- |
- |
019 [2] 19, 299 💬 |
380 |
Ogt918 |
- |
- |
- |
- |
019 [1] 19 💬 |
381 |
Ogt923 |
- |
- |
- |
- |
019 [1] 19 💬 |
382 |
Olenasufligene relduparvovec |
Olenasufligene relduparvovec |
- |
- |
- |
019 [1] 19 💬 |
383 |
Olipudase alfa |
Olipudase alfa |
[1] D10820 D10820 💬 |
SMPD1 [1] SMPD1 💬 |
Lysosome [5] Lysosome, Metabolic pathways, Necroptosis, Sphingolipid metabolism, Sphingolipid signaling pathway |
019 [1] 19 💬 |
384 |
Olipudase alfa (rhasm) |
Olipudase alfa |
[1] D10820 D10820 💬 |
SMPD1 [1] SMPD1 💬 |
Lysosome [5] Lysosome, Metabolic pathways, Necroptosis, Sphingolipid metabolism, Sphingolipid signaling pathway |
019 [1] 19 💬 |
385 |
Omnipaque |
- |
- |
- |
- |
019 [1] 19 💬 |
386 |
Oral migalastat hcl |
Migalastat |
[1] D10359 D10359 💬 |
- |
- |
019 [1] 19 💬 |
387 |
Osteopetrosis haploidentical only preparative regimen |
- |
- |
- |
- |
019 [5] 19, 20, 125, 234, 326 💬 |
388 |
Osteopetrosis only preparative regimen |
- |
- |
- |
- |
019 [5] 19, 20, 125, 234, 326 💬 |
389 |
Other: brief pain inventory questionnaire |
- |
- |
- |
- |
019 [1] 19 💬 |
390 |
Other: challenge agent: capsaicin |
Capsaicin |
[1] D00250 D00250 💬 |
TRPV1 [1] TRPV1 💬 |
Inflammatory mediator regulation of TRP channels [2] Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
019 [1] 19 💬 |
391 |
Other: control |
- |
- |
- |
- |
006 [8] 6 , 19, 70, 75, 85, 97, 162, 193 💬 |
392 |
Other: cysteamine bitartrate |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
393 |
Other: electroencephalogram (eeg) awake andextended overnight |
- |
- |
- |
- |
019 [1] 19 💬 |
394 |
Other: fluorescein angiography |
Fluorescein |
[2] D01261 D01261, D02024 D02024 💬 |
- |
- |
019 [1] 19 💬 |
395 |
Other: general and neurological examination |
- |
- |
- |
- |
019 [1] 19 💬 |
396 |
Other: ketogenic diet |
- |
- |
- |
- |
019 [1] 19 💬 |
397 |
Other: neurology exam |
- |
- |
- |
- |
019 [1] 19 💬 |
398 |
Other: no it treatment |
- |
- |
- |
- |
019 [1] 19 💬 |
399 |
Other: palliative care |
- |
- |
- |
- |
019 [5] 19, 65, 120, 160, 326 💬 |
400 |
Other: potable water |
Water |
[1] D00001 D00001 💬 |
- |
- |
019 [1] 19 💬 |
401 |
Other: quality of life questionnaire |
- |
- |
- |
- |
019 [1] 19 💬 |
402 |
Other: sham |
- |
- |
- |
- |
019 [2] 19, 301 💬 |
403 |
Other: vital signs |
- |
- |
- |
- |
019 [1] 19 💬 |
404 |
Otl-200 dispersion for infusion |
- |
- |
- |
- |
019 [1] 19 💬 |
405 |
Oxygen |
Oxygen |
[1] D00003 D00003 💬 |
- |
- |
006 [18] 6 , 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 294, 299, 330 💬 |
406 |
Paricalcitol |
Paricalcitol |
[1] D00930 D00930 💬 |
VDR [1] VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption [4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
019 [3] 19, 66, 218 💬 |
407 |
Pegunigalsidase alfa |
Pegunigalsidase alfa |
[1] D11685 D11685 💬 |
- |
- |
019 [1] 19 💬 |
408 |
Pegunigalsidase alpha |
- |
- |
- |
- |
019 [1] 19 💬 |
409 |
Pending |
- |
- |
- |
- |
013 [6] 13, 19, 96, 97, 113, 302 💬 |
410 |
Pentosan polysulfat sp 54® injection solution |
- |
- |
- |
- |
019 [1] 19 💬 |
411 |
Pentosan polysulfate |
Pentosan polysulfate |
[1] D05428 D05428 💬 |
- |
- |
019 [3] 19, 26, 226 💬 |
412 |
Pentosan polysulfate sodium |
Pentosan polysulfate |
[1] D05428 D05428 💬 |
- |
- |
019 [1] 19 💬 |
413 |
Pentosan polysulphate sp54 |
- |
- |
- |
- |
019 [1] 19 💬 |
414 |
Pentosan polysulphate sp54® |
- |
- |
- |
- |
019 [1] 19 💬 |
415 |
Perdix |
- |
- |
- |
- |
019 [1] 19 💬 |
416 |
Plant cell expressed recombinant glucocerebrosidase (prgcd) |
Taliglucerase alfa |
[1] D09675 D09675 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
417 |
Plant cell recombinant glucocerebrosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
418 |
Plx-200 |
- |
- |
- |
- |
019 [1] 19 💬 |
419 |
Pr001 |
- |
- |
- |
- |
019 [1] 19 💬 |
420 |
Prednisone |
Prednisone |
[1] D00473 D00473 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [47] 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 |
421 |
Prevenar13 |
- |
- |
- |
- |
019 [2] 19, 265 💬 |
422 |
Prgcd |
Taliglucerase alfa |
[1] D09675 D09675 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
423 |
Procedure: 12 lead electrocardiogram |
- |
- |
- |
- |
019 [1] 19 💬 |
424 |
Procedure: 2-hour holter monitor |
Methamidophos |
- |
- |
- |
019 [1] 19 💬 |
425 |
Procedure: allogeneic stem cell transplantation |
- |
- |
- |
- |
019 [3] 19, 20, 62 💬 |
426 |
Procedure: blood draw |
- |
- |
- |
- |
006 [5] 6 , 19, 65, 231, 299 💬 |
427 |
Procedure: brain mri/mrs/fmri |
- |
- |
- |
- |
019 [1] 19 💬 |
428 |
Procedure: contrast sensitivity measurement |
- |
- |
- |
- |
019 [1] 19 💬 |
429 |
Procedure: dexa scan |
- |
- |
- |
- |
019 [3] 19, 46, 96 💬 |
430 |
Procedure: echocardiogram |
- |
- |
- |
- |
019 [1] 19 💬 |
431 |
Procedure: lumbar puncture |
- |
- |
- |
- |
006 [5] 6 , 13, 19, 96, 97 💬 |
432 |
Procedure: magnetic resonance imaging |
- |
- |
- |
- |
019 [1] 19 💬 |
433 |
Procedure: ophthalmology exam |
- |
- |
- |
- |
019 [1] 19 💬 |
434 |
Procedure: oxygen flow at the optic nerve head measurement |
Oxygen |
[1] D00003 D00003 💬 |
- |
- |
019 [1] 19 💬 |
435 |
Procedure: quantitative chemical shift imaging (qcsi) |
- |
- |
- |
- |
019 [1] 19 💬 |
436 |
Procedure: skeletal survey |
- |
- |
- |
- |
019 [1] 19 💬 |
437 |
Procedure: skin biopsy |
- |
- |
- |
- |
019 [2] 19, 84 💬 |
438 |
Procedure: slit lamp assessment and intra-ocular pressure measurement |
- |
- |
- |
- |
019 [1] 19 💬 |
439 |
Procedure: speech and modified barium swallow study |
Barium |
- |
- |
- |
019 [1] 19 💬 |
440 |
Procedure: stem cell transplant |
- |
- |
- |
- |
019 [5] 19, 20, 65, 164, 284 💬 |
441 |
Procedure: stem cell transplantation |
- |
- |
- |
- |
019 [6] 19, 51, 60, 62, 65, 326 💬 |
442 |
Procedure: surgery to implant human cns stem cells (hucns-sc) |
- |
- |
- |
- |
019 [1] 19 💬 |
443 |
Procedure: total body irradiation |
- |
- |
- |
- |
019 [6] 19, 20, 51, 60, 65, 285 💬 |
444 |
Procedure: urine collection |
- |
- |
- |
- |
019 [1] 19 💬 |
445 |
Procedure: visual field testing |
- |
- |
- |
- |
019 [1] 19 💬 |
446 |
Procedure: whole body protein turnover |
- |
- |
- |
- |
019 [4] 19, 46, 96, 299 💬 |
447 |
Procysbi |
- |
- |
- |
- |
019 [1] 19 💬 |
448 |
Prx-102 |
- |
- |
- |
- |
019 [1] 19 💬 |
449 |
Prx-102 (pegunigalsidase alfa) |
Pegunigalsidase alfa |
[1] D11685 D11685 💬 |
- |
- |
019 [1] 19 💬 |
450 |
Prx-112 |
- |
- |
- |
- |
019 [1] 19 💬 |
451 |
Prx102 |
- |
- |
- |
- |
019 [1] 19 💬 |
452 |
Ptc124 |
- |
- |
- |
- |
019 [4] 19, 113, 246, 299 💬 |
453 |
Pyrimethamine |
Pyrimethamine |
[1] D00488 D00488 💬 |
- |
- |
002 [4] 2 , 4 , 19, 65 💬 |
454 |
Raav 2/6 hids donor |
- |
- |
- |
- |
019 [1] 19 💬 |
455 |
Raav2/5-hnaglu |
- |
- |
- |
- |
019 [1] 19 💬 |
456 |
Raav2/6 left zfn vector |
- |
- |
- |
- |
019 [1] 19 💬 |
457 |
Raav2/6 right zfn vector |
- |
- |
- |
- |
019 [1] 19 💬 |
458 |
Raav9.cmv.hnaglu |
- |
- |
- |
- |
019 [1] 19 💬 |
459 |
Radiation: total body irradiation with marrow boosting |
- |
- |
- |
- |
019 [2] 19, 234 💬 |
460 |
Rebisufligene etisparvovec |
- |
- |
- |
- |
019 [1] 19 💬 |
461 |
Recombinant adeno-associated virus 2/6 vector encoding the cdna for human alpha galactosidase a |
- |
- |
- |
- |
019 [1] 19 💬 |
462 |
Recombinant alpha-galactosidase a |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
463 |
Recombinant human acid sphingomyelinase (rhasm) |
- |
- |
- |
- |
019 [1] 19 💬 |
464 |
Recombinant human alpha-galactosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
465 |
Recombinant human alpha-galactosidase abbreviated as r-h-alpha-gal |
- |
- |
- |
- |
019 [1] 19 💬 |
466 |
Recombinant human alpha-mannosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
467 |
Recombinant human alpha-n-acetylglucosaminidase (rhnaglu) |
- |
- |
- |
- |
019 [1] 19 💬 |
468 |
Recombinant human arylsulfatase a |
- |
- |
- |
- |
019 [1] 19 💬 |
469 |
Recombinant human arylsulfatase a (rhasa) |
- |
- |
- |
- |
019 [1] 19 💬 |
470 |
Recombinant human arylsulfatase a (rhasa, |
- |
- |
- |
- |
019 [1] 19 💬 |
471 |
Recombinant human arysulfatase b, recombinant human n-acetylgalactosamine 4-sulfatase |
- |
- |
- |
- |
019 [1] 19 💬 |
472 |
Recombinant human beta glucuronidase |
- |
- |
- |
- |
019 [1] 19 💬 |
473 |
Recombinant human beta-glucuronidase |
Vestronidase alfa |
[1] D11004 D11004 💬 |
GUSB [1] GUSB 💬 |
Ascorbate and aldarate metabolism [8] Ascorbate and aldarate metabolism, Biosynthesis of cofactors, Drug metabolism - other enzymes, Glycosaminoglycan degradation, Lysosome, Metabolic pathways, Pentose and glucuronate interconversions, Porphyrin and chlorophyll metabolism |
019 [1] 19 💬 |
474 |
Recombinant human beta-glucuronidase (rhgus) |
Vestronidase alfa |
[1] D11004 D11004 💬 |
GUSB [1] GUSB 💬 |
Ascorbate and aldarate metabolism [8] Ascorbate and aldarate metabolism, Biosynthesis of cofactors, Drug metabolism - other enzymes, Glycosaminoglycan degradation, Lysosome, Metabolic pathways, Pentose and glucuronate interconversions, Porphyrin and chlorophyll metabolism |
019 [1] 19 💬 |
475 |
Recombinant human betaglucuronidase |
- |
- |
- |
- |
019 [1] 19 💬 |
476 |
Recombinant human derived macrophage-targeted beta-glucocerebrosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
477 |
Recombinant human derived macrophage-targeted ß-glucocerebrosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
478 |
Recombinant human glucerebrosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
479 |
Recombinant human glucocerebrosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
480 |
Recombinant human glucocerebrosidase (prgcd) |
Taliglucerase alfa |
[1] D09675 D09675 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
481 |
Recombinant human heparan n-sulfatase |
- |
- |
- |
- |
019 [1] 19 💬 |
482 |
Recombinant human heparan n-sulfatase (rhhns) |
- |
- |
- |
- |
019 [1] 19 💬 |
483 |
Recombinant human heparan n-sulfatase [rhhns] |
- |
- |
- |
- |
019 [1] 19 💬 |
484 |
Recombinant human heparan nsulfatase (rhhns) |
- |
- |
- |
- |
019 [1] 19 💬 |
485 |
Recombinant human lysosomal acid lipase |
- |
- |
- |
- |
019 [1] 19 💬 |
486 |
Recombinant human lysosomal acid lipase (rhlal) |
- |
- |
- |
- |
019 [1] 19 💬 |
487 |
Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa) |
Cholesterol |
[1] D00040 D00040 💬 |
- |
- |
019 [1] 19 💬 |
488 |
Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa) |
Cholesterol |
[1] D00040 D00040 💬 |
- |
- |
019 [1] 19 💬 |
489 |
Recombinant human lysosomal alpha-mannosidase |
- |
- |
- |
- |
019 [1] 19 💬 |
490 |
Recombinant human n-acetylgalactosamine 4-sulfatase |
- |
- |
- |
- |
019 [1] 19 💬 |
491 |
Recombinant human n-acetylgalactosamine 6-sulfatase, bmn 110 |
- |
- |
- |
- |
019 [1] 19 💬 |
492 |
Recombinant human n-acetylgalactosamine 6-sulfatase, bmn 110 drug substance |
- |
- |
- |
- |
019 [1] 19 💬 |
493 |
Recombinant human n-acetylgalactosamine-6-sulfatase (rhgalns) |
Elosulfase alfa |
[1] D10333 D10333 💬 |
GALNS [1] GALNS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
494 |
Recombinant human n-acetylgalactosamine-6-sulfatase, bmn 110 |
Elosulfase alfa |
[1] D10333 D10333 💬 |
GALNS [1] GALNS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
495 |
Recombinant human n-acetylgalactosamine-6-sulfatase, bmn 110 drug substance |
Elosulfase alfa |
[1] D10333 D10333 💬 |
GALNS [1] GALNS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
496 |
Recombinant human nacetylgalactosamine- |
- |
- |
- |
- |
019 [1] 19 💬 |
497 |
Recombinant human tripeptidyl peptidase-1 |
- |
- |
- |
- |
019 [1] 19 💬 |
498 |
Recombinant human tripeptidyl peptidase-1 (rhtpp1) |
- |
- |
- |
- |
019 [1] 19 💬 |
499 |
Reduced intensity conditioning |
- |
- |
- |
- |
019 [2] 19, 65 💬 |
500 |
Reminder capsules |
- |
- |
- |
- |
019 [1] 19 💬 |
501 |
Reminder product |
- |
- |
- |
- |
019 [1] 19 💬 |
502 |
Replagal |
- |
- |
- |
- |
019 [1] 19 💬 |
503 |
Replagal (agalsidase alfa) |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
504 |
Replagal agalsidase alfa |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
505 |
Rh growth hormone |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
019 [1] 19 💬 |
506 |
Rharsa |
- |
- |
- |
- |
019 [1] 19 💬 |
507 |
Rhasa |
- |
- |
- |
- |
019 [1] 19 💬 |
508 |
Rhasm |
- |
- |
- |
- |
019 [1] 19 💬 |
509 |
Rhgus |
- |
- |
- |
- |
019 [1] 19 💬 |
510 |
Rhhns-10 mg |
- |
- |
- |
- |
019 [1] 19 💬 |
511 |
Rhhns-45 mg |
- |
- |
- |
- |
019 [1] 19 💬 |
512 |
Rhhns-90 mg |
- |
- |
- |
- |
019 [1] 19 💬 |
513 |
Rhidu (recombinant human-alpha-l-iduronidase) |
- |
- |
- |
- |
019 [1] 19 💬 |
514 |
Rhlaman |
Velmanase alfa |
[1] D11024 D11024 💬 |
MAN2B1 [1] MAN2B1 💬 |
Lysosome [2] Lysosome, Other glycan degradation |
019 [1] 19 💬 |
515 |
Rhnaglu |
- |
- |
- |
- |
019 [1] 19 💬 |
516 |
Rhnaglu radiolabelled |
- |
- |
- |
- |
019 [1] 19 💬 |
517 |
Rhnaglu-igf2 |
- |
- |
- |
- |
019 [1] 19 💬 |
518 |
Rimiducid |
Rimiducid |
[1] D11195 D11195 💬 |
CASP9 [1] CASP9 💬 |
Alzheimer disease [34] Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Colorectal cancer, Endometrial cancer, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Huntington disease, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Measles, Non-small cell lung cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parkinson disease, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prion disease, Prostate cancer, Small cell lung cancer, Thyroid hormone signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Viral myocarditis, p53 signaling pathway |
019 [6] 19, 60, 65, 284, 285, 326 💬 |
519 |
Rituximab |
Rituximab |
[1] D02994 D02994 💬 |
MS4A1 [1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
011 [47] 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
520 |
Rivogenlecleucel |
- |
- |
- |
- |
019 [6] 19, 60, 65, 284, 285, 326 💬 |
521 |
Rp 103 |
- |
- |
- |
- |
008 [2] 8 , 19 💬 |
522 |
Rp103 |
- |
- |
- |
- |
008 [2] 8 , 19 💬 |
523 |
Rvx000222 |
- |
- |
- |
- |
019 [1] 19 💬 |
524 |
Saf-301 |
- |
- |
- |
- |
019 [1] 19 💬 |
525 |
Saline solution for injection |
- |
- |
- |
- |
019 [1] 19 💬 |
526 |
Sar402671, gz402671 or gz/sar402671 |
- |
- |
- |
- |
006 [3] 6 , 19, 67 💬 |
527 |
Sb-318 |
- |
- |
- |
- |
019 [1] 19 💬 |
528 |
Sb-47171 |
- |
- |
- |
- |
019 [1] 19 💬 |
529 |
Sb-47898 |
- |
- |
- |
- |
019 [1] 19 💬 |
530 |
Sb-913 |
- |
- |
- |
- |
019 [1] 19 💬 |
531 |
Sb-a6p-hrl donor vector |
- |
- |
- |
- |
019 [1] 19 💬 |
532 |
Sb-fix |
- |
- |
- |
- |
019 [1] 19 💬 |
533 |
Sb-idua |
- |
- |
- |
- |
019 [1] 19 💬 |
534 |
Sbc-102 |
Sebelipase alfa |
[1] D10377 D10377 💬 |
LIPA [1] LIPA 💬 |
Cholesterol metabolism [3] Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 [1] 19 💬 |
535 |
Sbc-102, recombinant human lysosomal acid lipase |
Sebelipase alfa |
[1] D10377 D10377 💬 |
LIPA [1] LIPA 💬 |
Cholesterol metabolism [3] Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 [1] 19 💬 |
536 |
Sbc-103 |
- |
- |
- |
- |
019 [1] 19 💬 |
537 |
Scaav9.u1a.hsgsh |
- |
- |
- |
- |
019 [1] 19 💬 |
538 |
Scaav9.u1a.sgsh |
- |
- |
- |
- |
019 [1] 19 💬 |
539 |
Sebelipasa alfa |
Sebelipase alfa |
[1] D10377 D10377 💬 |
LIPA [1] LIPA 💬 |
Cholesterol metabolism [3] Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 [1] 19 💬 |
540 |
Sebelipase alfa |
Sebelipase alfa |
[1] D10377 D10377 💬 |
LIPA [1] LIPA 💬 |
Cholesterol metabolism [3] Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 [1] 19 💬 |
541 |
Sebelipase alfa (sbc-102) |
Sebelipase alfa |
[1] D10377 D10377 💬 |
LIPA [1] LIPA 💬 |
Cholesterol metabolism [3] Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 [1] 19 💬 |
542 |
Sebelipase alfa 0.35 mg/kg |
Sebelipase alfa |
[1] D10377 D10377 💬 |
LIPA [1] LIPA 💬 |
Cholesterol metabolism [3] Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 [1] 19 💬 |
543 |
Sebelipase alfa 1 mg/kg |
Sebelipase alfa |
[1] D10377 D10377 💬 |
LIPA [1] LIPA 💬 |
Cholesterol metabolism [3] Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 [1] 19 💬 |
544 |
Sebelipase alfa 3 mg/kg |
Sebelipase alfa |
[1] D10377 D10377 💬 |
LIPA [1] LIPA 💬 |
Cholesterol metabolism [3] Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 [1] 19 💬 |
545 |
Shp611 |
- |
- |
- |
- |
019 [1] 19 💬 |
546 |
Sirolimus |
Sirolimus |
[1] D00753 D00753 💬 |
MTOR [1] MTOR 💬 |
AMPK signaling pathway [50] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
006 [35] 6 , 13, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 💬 |
547 |
Sobi003 |
- |
- |
- |
- |
019 [1] 19 💬 |
548 |
Sofosbuvir |
Sofosbuvir |
[1] D10366 D10366 💬 |
- |
- |
019 [1] 19 💬 |
549 |
Somatropin |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
002 [16] 2 , 3 , 19, 46, 74, 75, 78, 96, 113, 187, 193, 195, 265, 274, 276, 299 💬 |
550 |
Somatropin (dna origin) |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
019 [1] 19 💬 |
551 |
Ss-mercaptoethylamine hydrochloride & 2-aminoethanethiol hydrochloride |
Cysteamine |
[2] D03634 D03634, D03635 D03635 💬 |
- |
- |
019 [1] 19 💬 |
552 |
St-920 |
- |
- |
- |
- |
019 [1] 19 💬 |
553 |
Stem cell transplantation |
- |
- |
- |
- |
013 [10] 13, 19, 20, 46, 65, 90, 125, 164, 234, 326 💬 |
554 |
Sub195712 |
- |
- |
- |
- |
019 [1] 19 💬 |
555 |
Taliglucerase alfa |
Taliglucerase alfa |
[1] D09675 D09675 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
556 |
Taliglucerase alfa - recombinant human glucocerebrosidase |
Taliglucerase alfa |
[1] D09675 D09675 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
557 |
Tbd |
- |
- |
- |
- |
019 [4] 19, 86, 276, 299 💬 |
558 |
Thiotepa |
Thiotepa |
[1] D00583 D00583 💬 |
- |
- |
013 [11] 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 💬 |
559 |
Thiotepa--escalated dose |
Thiotepa |
[1] D00583 D00583 💬 |
- |
- |
019 [4] 19, 20, 65, 284 💬 |
560 |
Thiotepa--single daily dose |
Thiotepa |
[1] D00583 D00583 💬 |
- |
- |
019 [4] 19, 20, 65, 284 💬 |
561 |
Thyroxine |
Levothyroxine |
[2] D01010 D01010, D08125 D08125 💬 |
THRA [2] THRA, THRB 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
019 [1] 19 💬 |
562 |
Trappsol cyclo |
- |
- |
- |
- |
019 [1] 19 💬 |
563 |
Treosulfan |
Treosulfan |
[1] D07253 D07253 💬 |
- |
- |
013 [3] 13, 19, 65 💬 |
564 |
Triapin |
- |
- |
- |
- |
019 [1] 19 💬 |
565 |
Triapin& triapin mite |
- |
- |
- |
- |
019 [1] 19 💬 |
566 |
Tropicamide |
Tropicamide |
[1] D00397 D00397 💬 |
CHRM1 [5] CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease [13] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 [2] 6 , 19 💬 |
567 |
Unrelated umbilical cord blood transplant |
- |
- |
- |
- |
019 [1] 19 💬 |
568 |
Uplyso |
- |
- |
- |
- |
019 [1] 19 💬 |
569 |
Usan: sebelipasa alfa |
Sebelipase alfa |
[1] D10377 D10377 💬 |
LIPA [1] LIPA 💬 |
Cholesterol metabolism [3] Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 [1] 19 💬 |
570 |
Usan: sebelipase alpha |
- |
- |
- |
- |
019 [1] 19 💬 |
571 |
Ux003 |
- |
- |
- |
- |
019 [1] 19 💬 |
572 |
Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana |
- |
- |
- |
- |
019 [1] 19 💬 |
573 |
Velaglucerase alfa |
Velaglucerase alfa |
[1] D09029 D09029 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
574 |
Velaglucerase alfa (vpriv) |
Velaglucerase alfa |
[1] D09029 D09029 💬 |
GBA [1] GBA 💬 |
Lysosome [4] Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 [1] 19 💬 |
575 |
Velaglucerasi alfa |
- |
- |
- |
- |
019 [1] 19 💬 |
576 |
Velmanase alfa |
Velmanase alfa |
[1] D11024 D11024 💬 |
MAN2B1 [1] MAN2B1 💬 |
Lysosome [2] Lysosome, Other glycan degradation |
019 [1] 19 💬 |
577 |
Velmanase alfa (e.g. lamazym) |
Velmanase alfa |
[1] D11024 D11024 💬 |
MAN2B1 [1] MAN2B1 💬 |
Lysosome [2] Lysosome, Other glycan degradation |
019 [1] 19 💬 |
578 |
Venglustat |
Venglustat |
[1] D11633 D11633 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
006 [3] 6 , 19, 67 💬 |
579 |
Venglustat (gz/sar402671) |
Venglustat |
[1] D11633 D11633 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
580 |
Venglustat gz402671 |
Venglustat |
[1] D11633 D11633 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [2] 19, 67 💬 |
581 |
Vimizim® (elosulfase alfa) |
Elosulfase alfa |
[1] D10333 D10333 💬 |
GALNS [1] GALNS 💬 |
Glycosaminoglycan degradation [3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 [1] 19 💬 |
582 |
Vitamin d |
Vitamin D |
- |
- |
- |
013 [21] 13, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 274, 298, 299 💬 |
583 |
Vorinostat |
Vorinostat |
[1] D06320 D06320 💬 |
HDAC1 [11] HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 💬 |
Alcoholism [17] Alcoholism, Amphetamine addiction, Amyotrophic lateral sclerosis, Apelin signaling pathway, Cell cycle, Chronic myeloid leukemia, Epstein-Barr virus infection, Human papillomavirus infection, Huntington disease, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, Notch signaling pathway, Pathways in cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Viral carcinogenesis |
019 [3] 19, 75, 96 💬 |
584 |
Vpriv |
- |
- |
- |
- |
019 [1] 19 💬 |
585 |
Vpriv - 400 u - polvere per soluzione per infusione - uso endovenoso - flaconcino(vetro) 1 flaconcino |
- |
- |
- |
- |
019 [1] 19 💬 |
586 |
Vpriv 400 units powder for solution of infusion |
- |
- |
- |
- |
019 [1] 19 💬 |
587 |
Vpriv ®, |
- |
- |
- |
- |
019 [1] 19 💬 |
588 |
Vpriv® |
- |
- |
- |
- |
019 [1] 19 💬 |
589 |
Vts-270 |
- |
- |
- |
- |
019 [1] 19 💬 |
590 |
Warfarin |
Warfarin |
[3] D00564 D00564, D01280 D01280, D08682 D08682 💬 |
NQO1 [2] NQO1, VKORC1 💬 |
Biosynthesis of cofactors [6] Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
006 [11] 6 , 8 , 13, 19, 46, 49, 66, 85, 88, 96, 97 💬 |
591 |
Water |
Water |
[1] D00001 D00001 💬 |
- |
- |
002 [22] 2 , 5 , 6 , 13, 17, 19, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 💬 |
592 |
Zavesca |
- |
- |
- |
- |
019 [3] 19, 256, 299 💬 |
593 |
Zavesca (miglustat) |
Miglustat |
[1] D05032 D05032 💬 |
UGCG [1] UGCG 💬 |
Metabolic pathways [2] Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
594 |
Zavesca 84cps 100mg |
- |
- |
- |
- |
019 [1] 19 💬 |
595 |
Zestoretic 10,20 |
- |
- |
- |
- |
019 [1] 19 💬 |
596 |
Zestoric |
- |
- |
- |
- |
019 [1] 19 💬 |
597 |
Zestril |
- |
- |
- |
- |
019 [3] 19, 67, 222 💬 |